Diabetic Macular Edema

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

Retinal imaging tests are providing material to train and test decision support systems.

Novel therapies are shifting the paradigm in care of retinal diseases

Study results show that aflibercept-treated eyes are protected.

John Wells, MD, presents efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials during the virtual ARVO meeting.

Easier, more accessible functional studies have been made possible

Numerous studies will be completed during the next few years, and many new studies are being developed.

Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium highlights and thoughts on current treatments options for DME and exudative AMD are discussed.

Anat Loewenstein, MD, MHA, explores dual Ang-2/VEGF-A inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Study highlights role of demographic and socioeconomic characteristics in treatment

The hope is that future analyses would show more patients completing the pathway and a lower rate of missed appointments.

The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.

Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema.

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.